LNSR

LENSAR, Inc.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc. (LNSR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Momentum (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B+
Factor Score 3.5 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 10.7
EV / EBITDA 24.4
Rev Growth YoY -1.3%
Gross Margin 52.0%
Price Return 3M -42.7%
Price Return 12M -55.0%
Catalyst Signal 0.00
Market Cap $57.8M
TTM Revenue $60.1M
Price / Sales 1.0
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) C (2.2) B+ (3.5) C- (2.0) C+ (2.6) C+ (2.7)
2026-11-06 B- (2.9) C+ (2.5) B (3.3) B- (3.0) C+ (2.7) B- (2.9)
2026-10-30 B- (2.9) C+ (2.5) B (3.3) B (3.2) C+ (2.7) B- (2.9)
2026-10-23 B- (2.9) C+ (2.5) B (3.3) B- (3.1) C+ (2.6) B- (2.9)
2026-10-16 B- (2.9) C+ (2.5) B (3.3) B- (3.0) C+ (2.6) B- (2.9)
Page 1 of 3